Embecta Corp. (EMBC) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, EMBC scores 74 out of 100, a letter grade of B, with the verdict label "Roarable Buy — Good Risk/Reward." The five pillars are:

• Fundamental Cash Engine: 19 / 20. Per the RQD rating, this pillar reflects an ROIC of 35.5% alongside an FCF yield of 0%. The strong return on invested capital is the primary upside driver in this pillar, while the zero FCF yield is a valuation tradeoff: the reported free cash flow is not being returned to shareholders at the current market price.
• Whale 13F Flow: 11 / 20. Per the RQD rating, this pillar measures institutional accumulation and options positioning. The modest score suggests institutional flow is a weaker supporting factor than the fundamentals. Holder data in the source is not available, so the underlying positioning cannot be examined further here.
• Insider Conviction: 17 / 20. Per the RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. This is a relatively strong score, though the underlying trade detail is not available in the source data.
• Macro Regime Fit: 12 / 20. Per the RQD rating, this pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves; the score indicates moderate rather than favorable macro alignment.
• Forensic Balance Sheet: 15 / 20. Per the RQD rating, this pillar reflects an Altman Z of 2.5, a Piotroski F of 7/9, and a Debt/Equity of 0.5. These support solvency and fundamental quality, but the reported debt level is a key consideration for a prospective investor.

Taken together, the rating points to strong cash-generation economics and reasonable forensic health, offset by weaker institutional flow and macro fit. For a prospective investor evaluating the stock today, the central question is whether the high ROIC and low trailing valuation outweigh the leverage and the absence of free-cash-flow yield.

Embecta Corp. (EMBC) is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. Per the company profile, its market capitalization is $0.4B. Per the market data, its gross margin is 62.6%, operating margin 22.4%, and net margin 8.8%. Product, customer, and revenue-model detail is not available in source data.

The news wire contains six items dated within roughly the prior 15 hours of the data timestamp. Per the news feed, the items are labeled as follows:

• Risk Watch (RED): "What Embecta Bears Saw Before A 55% Drop" (Yahoo Finance) and "Did Embecta's 52% Fall Catch You Out? What Investors Missed" (Simply Wall St). Both reference large declines in the stock, but the underlying causes are not available in source data.
• Market Wire (YELLOW): A Stocktwits general overview; an analyst-insights piece from The Globe and Mail naming EMBC alongside AIRS; a law-firm notice from The National Law Review stating that Bronstein, Gewirtz & Grossman, LLC is investigating Embecta Corp. (EMBC) and encouraging stockholders to connect; and a kalkine.ca item noting a 6.86% move on light volume with no catalyst found.

Per the news feed, the investigation notice is the most specific item; its substance and any allegations are not available in source data. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What drove the reported 52–55% declines referenced in the news wire, and are they tied to the investigation notice?
• What is the nature of the investigation referenced by the law-firm notice, and what allegations, if any, are involved?
• Why is the FCF yield 0% when reported FY 2025 free cash flow is $182.4M, and how does that reconcile with the market capitalization?
• What is the composition of the $1352.9M debt, including maturities and refinancing exposure?
• What EPS values were reported for the financial periods, given that the source lists them as N/A?